Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial.

Yvo J M Op den KampMarlies de LigtBas DautzenbergEsther KornipsRussell EsterlineMatthijs K C Hesselink Joris HoeksVera B Schrauwen-HinderlingBas HavekesJan OscarssonEsther Phielix Patrick Schrauwen

Published in: Diabetes care (2021)

Dapagliflozin treatment for 5 weeks resulted in major adjustments of metabolism mimicking caloric restriction, increased fat oxidation, improved hepatic and adipose insulin sensitivity, and improved 24-h energy metabolism.

Keyphrases

double blind
placebo controlled
phase iii
clinical trial
adipose tissue
study protocol
phase ii
open label
insulin resistance
hydrogen peroxide
type diabetes
metabolic syndrome
nitric oxide
gestational age
skeletal muscle